DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong ...

Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to ...

The CGM market is expected to experience double-digit percentage growth over the next five years, reaching nearly $29 billion ...

Since last year, DexCom ( DXCM +5.54%) has faced a series of issues that have sunk its stock price. The medical device ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

The CGM market is an exciting, fast-growing, multibillion-dollar medtech sector, according to our new Medtech Market ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...